Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Markóczy, Zsolt, Sárosi, Veronika, Kudaba, Iveta, Gálffy, Gabriella, Turay, Ülkü Yilmaz, Demirkazik, Ahmet, Purkalne, Gunta, Somfay, Attila, Pápai-Székely, Zsolt, Rásó, Erzsébet, Ostoros, Gyula: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
BMC CANCER, 18 (1). Azonosító: 598-Terjedelem: 7 p. ISSN 1471-2407 (2018)

[img]
Preview
Text
12885_2018_Article_4283.pdf - Published Version

Download (601kB) | Preview
Item Type: Article
Journal or Publication Title: BMC CANCER
Date: 2018
Volume: 18
Number: 1
Page Range: Azonosító: 598-Terjedelem: 7 p
ISSN: 1471-2407
Faculty: Faculty of Medicine
Institution: Szegedi Tudományegyetem
SWORD language: angol
MTMT id: 3381213
DOI id: https://doi.org/10.1186/s12885-018-4283-z
Date Deposited: 2019. Apr. 23. 11:14
Last Modified: 2019. Apr. 23. 11:14
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/15190
Web of Science® Times Cited: 4 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year